MSB 2.29% $1.28 mesoblast limited

Ann: Class Action Resolution, page-160

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 15,726 Posts.
    lightbulb Created with Sketch. 5754
    .... amazing - here we are a week later and you are still going on with the same unsubstantiated claims / conjecture on the matter ?


    I am tipping a partnership announcement will follow in short order at a premium .... I hear poor old @Sector is going off trying to remain relevant over the pond rambling on about my posts on the previous partnership deals without giving credence to the fact that Mesoblast's Rexlemestrocel-L as an indication is in a much stronger partnership negotiating position than it was over a decade ago.


    With great results from multiple CHF trials (including phase 3 DREAM-HF trial) and of course now the FDA's support for an Accelerated Approval pathway for the treatment of patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD), what big pharma wouldn't be interested now with all that's on offer and of course with the CA being resolved with a nuisance payment to the lawyers ? One would think a CHF partnership in 2024 would dwarf the previous deal done over a decade ago with much less on offer, which is below for those that haven't seen the Cephalon numbers back in 2010


    GLTAH


    upload_2024-8-26_9-2-11.png



    https://www.fiercebiotech.com/biotech/cephalon-strikes-record-2b-stem-cell-pact-mesoblast


    Cephalon strikes record $2B stem cell pact with Mesoblast



    Regenerative medicine just got a big player to enter the game. Cephalon has locked itself in a tight embrace with Australia's Mesoblast, agreeing to pay $130 million upfront, $220 million for a 20 percent stake in the company and offering up to $1.7 billion in milestones in a high-stakes gamble on the biotech's stem cell programs.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.28
Change
-0.030(2.29%)
Mkt cap ! $1.461B
Open High Low Value Volume
$1.32 $1.35 $1.28 $1.677M 1.289M

Buyers (Bids)

No. Vol. Price($)
10 44452 $1.28
 

Sellers (Offers)

Price($) Vol. No.
$1.29 23596 1
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.